IGF2 and neoplasm: MEDI-573 (mAb to IGF-I and IGF-II) application inhibited tumor growth in a CRC female mouse model that over-expresses IGF-II, and this effect was enhanced if MEDI-573 was combined with other known therapeutics such as trastuzumab, AZD2014, AZD5363, selumetinib or cetuximab [211].